久久女女九九九|蜜臀国产原创中文|丁香五月美女自拍|欧美中文字幕视频在线

一、概述
　　
　　I. Introduction
　　
　　 深圳市第三人民醫(yī)院（南方科技大學第二附屬醫(yī)院）始建于1985年， 2010年12月醫(yī)院整體搬遷至新院址—深圳市龍崗區(qū)，是由深圳市政府創(chuàng)辦的一所大型現(xiàn)代化“強專科，大綜合”的市屬三級甲等傳染病?？蒲芯啃歪t(yī)院。主要承擔深圳市及周邊港、澳、珠海、東莞、惠州地區(qū)的傳染病與重大疫情的防控以及深圳市2000萬市民的綜合醫(yī)療服務。醫(yī)院積極響應深圳市政府“東進戰(zhàn)略”要求，以結核病為龍頭，感染性疾病為強?？频拇笮腿拙C合研究型醫(yī)院，同時圍繞 “一箭兩翼、三支柱八支撐”建設方針，以國家結核病臨床醫(yī)學研究中心為核心，以感染病國家臨床重點專科與器官移植中心建設兩翼，以肝病、艾滋病、新發(fā)傳染病及疑難感染病為支柱，全力建設八個綜合專科為支撐，打造廣東省高水平醫(yī)院。
　　
　　 The Third People's Hospital of Shenzhen (Second Affiliated Hospital of Southern University of Science and Technology) was founded in 1985. In December 2010, the Hospital was relocated to Buji Lilang, Longgang District, Shenzhen. It is a large-scale modern municipal hospital of Class III Grade A for infectious diseases founded by the Shenzhen Municipal Government with the characteristics of “Strong Specialty and Comprehensiveness”. It is mainly responsible for the prevention and control of infectious diseases and major epidemic diseases in Shenzhen and Hong Kong, Macao, Zhuhai, Dongguan and Huizhou, as well as the comprehensive medical services for 20 million citizens in Shenzhen. Based on the requirement of "Eastward Development Strategy" of the Shenzhen Municipal Government, the Hospital takes tuberculosis as the leading subject and infectious diseases as the specialty. Focusing on the construction policy of “One Arrow, Two Wings, Three Pillars and Eight Supports”, it takes the National Tuberculosis Clinical Medical Research Center as the core, the National Key Clinical Specialties and Organ Transplantation Center for Infectious Diseases as the two wings, the liver diseases, AIDS, emerging infectious diseases and difficult infectious diseases as the pillars, and eight comprehensive specialties as the support, to build the medical highland of Guangdong Province.
　　
　　
　　
　　醫(yī)院占地面積10萬平方米，現(xiàn)有建筑面積21.5萬平方米，2019年總床位達到1600張。改擴建二期工程完成后，醫(yī)院總建筑面積超過43萬平方米，總床位將達到2300張。是目前國內(nèi)醫(yī)院中設計較先進、設備配置較高的醫(yī)院之一?，F(xiàn)有員工1564人，其中高級職稱283人，博士后20人，博、碩士380人。享受國務院特殊津貼專家2人，享受深圳市特殊津貼專家2人，省市學科帶頭人18人，現(xiàn)有博士研究生導師5人，碩士研究生導師30人。為南方科技大學第二附屬醫(yī)院、廣東醫(yī)科大學非直屬附屬醫(yī)院、中山大學、武漢大學、湖北中醫(yī)藥大學博士及碩士研究生聯(lián)合培養(yǎng)單位，南華大學實習基地。
　　
　　The Hospital covers an area of 100,000 square meters, with an existing building area of 215,000 square meters and a total of 1,600 beds. After the completion of the second phase of the reconstruction and expansion project, the total construction area of the Hospital will exceed 430,000 square meters, and the total number of beds will reach 2,300. It is one of the Chinese hospitals with advanced design and equipment allocation. It has 1,564 employees, including 283 with senior titles, 20 with post-doctoral degrees, and 380 with doctoral and master degrees. Among them, there are 2 experts with special allowances from the State Council, 2 experts with special allowances from Shenzhen, and 18 foregoers of provincial and municipal disciplines, and there are 5 doctoral supervisors and 30 master supervisors. It is the joint training unit for doctor and master students of the Second Affiliated Hospital of Southern University of Science and Technology, the Non-affiliated Hospital of Guangdong Medical University, Sun Yat-sen University, Wuhan University, and Hubei University of Traditional Chinese Medicine, and the internship base of Nanhua University.
　　
　　
　　二、學科建設與影響力
　　
　　 II. Discipline Construction and Influences
　　
　　 醫(yī)院大力推動重點學科建設，先后建成包括感染病國家臨床重點專科在內(nèi)的15個國家及省市重點?？?、重點實驗室。感染病科成立于1985年，現(xiàn)有床位385張，由結核病科、肝病科、艾滋病科、傳染病科、感染ICU、人工肝室、深圳市肝病研究所、廣東省新發(fā)傳染病診治重點實驗室等組成，下設有肝病、肺病、艾滋病、新發(fā)傳染病4個醫(yī)學中心。在32年的發(fā)展歷程中，感染科以其獨有的特色和優(yōu)勢不斷發(fā)展壯大，綜合實力處于國內(nèi)同行列先進水平。2003年感染病科被評為廣東省傳染病特色專科；2005年肝病專業(yè)、艾滋病專業(yè)、結核病專業(yè)同時成為國家臨床藥物試驗基地；2006年醫(yī)院成為中國中西醫(yī)結合學會傳染病專業(yè)委員會的主任委員單位；2011年肝病、結核病和新發(fā)傳染病同時獲得深圳市臨床重點專科；2011、2012年又分別獲得廣東省新發(fā)傳染病診治重點實驗室與廣東省中醫(yī)傳染病診療技術實驗室。2013年感染科獲得國家感染病臨床重點?？?、廣東省感染性疾病臨床重點?？疲?018年醫(yī)院獲廣東省高水平醫(yī)院，并獲得國家結核病臨床醫(yī)學研究中心（深圳唯一，廣東省第三家）。目前已成為深、港、澳及珠、莞、惠等珠三角地區(qū)規(guī)模最大、設備最先進、功能最完善的感染病與傳染病診療與研究中心。
　　
　　 The hospital vigorously promotes the construction of key disciplines, and has built 15 national and provincial key specialties and key laboratories, including national key clinical specialties for infectious diseases. The Infectious Diseases Department was established in 1985, with 385 beds. It consists of the Tuberculosis Department, the Liver Disease Department, the AIDS Department, the Infectious Disease Department, the infectious ICU, the Artificial Liver Chamber, Shenzhen Institute of Liver Diseases, and the Key Laboratory of Diagnosis and Treatment of Emerging Infectious Diseases of Guangdong Province. It has four medical centers for liver diseases, lung diseases, AIDS and emerging infectious diseases. In its 32 years of development, the Infectious Disease Department has been growing with its unique characteristics and advantages, and its comprehensive strength is at the advanced level of the counterparts in China. In 2003, the Infectious Diseases Department was awarded the Specialty of Infectious Diseases in Guangdong Province; in 2005, the specialties of liver diseases, AIDS and tuberculosis became the national clinical drug testing bases; in 2006, the Hospital became the member unit of the Infectious Diseases Committee of the Chinese Society of Integrated Traditional Chinese and Western Medicine; in 2011, the liver disease, tuberculosis and emerging infectious diseases became the key clinical specialties in Shenzhen; In 2011 and 2012, it awarded the title of the Key Laboratory for Diagnosis and Treatment of Emerging Infectious Diseases in Guangdong Province and the Laboratory of TCM Infectious Disease Diagnosis and Treatment Technology in Guangdong Province respectively. In 2013, the Infectious Diseases Department was awarded the National Key Clinical Specialty of infectious Diseases and the Key Clinical Specialty of Infectious Diseases in Guangdong province. In 2018, the Hospital was awarded the High-level Hospital of Guangdong Province and the National Tuberculosis Clinical Medical Research Center (the only one in Shenzhen，the third one in Guangdong Province). At present, it has become the largest, most advanced and well-functioning center for the diagnosis, treatment and research of infectious diseases in Shenzhen, Hong Kong, Macao and the Pearl River Delta including Zhuhai, Dongguan and Huizhou.
　　
　　
　　 2003年醫(yī)院共收治非典確診病例46例，疑似病例390例。以預防性服藥為主的綜合性防治措施，實現(xiàn)了全院無一例SARS 病人院內(nèi)死亡，600多名職工無一例院內(nèi)感染的“深圳神話 ”。2006年通過有關特異性抗體免疫方法治愈深圳首例人禽流感患者，經(jīng)驗總結發(fā)表在《新英格蘭醫(yī)學》并被列入國家戰(zhàn)略物質(zhì)儲備。2009年全球豬流感大爆發(fā)，全院收治了來自全球五大洲66個國家和地區(qū)的1166例甲流隔離觀察患者。2013年至今我院共收治重癥禽流感患者44例，借助感染病重點實驗室平臺，對全部患者實現(xiàn)了精準診斷，指導臨床搶救治療，病死率9.1%，遠低于全國39.6%的病死率。
　　
　　 In 2003, 46 confirmed cases of SARS and 390 suspected cases were admitted to the Hospital. The comprehensive prevention and control measures based on preventive medication contributed to the "Shenzhen Myth" that no SARS patient died and no employees were infected in the Hospital. In 2006, the first patient of human avian influenza in Shenzhen was cured by specific antibody immunization. The experience summary was published in New England Medicine and listed in the national strategic material reserve. During the global swine flu outbreak in 2009, 1,166 isolated patients of H1N1 influenza in observation from 66 countries and regions on five continents were admitted to the hospital. Since 2013, 44 patients with severe avian influenza have been admitted to the hospital. With the help of the key laboratory platform of infectious diseases, accurate diagnosis has been achieved for all patients and clinical rescue and treatment has been guided. The fatality rate of the Hospital is 9.1%, which is far lower than that of 39.6% in the whole country.
　　
　　
　　借力市委市政府“三名工程”，醫(yī)院以“柔性引才”為基本思路，以培養(yǎng)“自身造血能力”為目的，2014年以來，引進了包括中國醫(yī)學科學院呼吸病學王辰院士團隊、中國科學院微生物所高福院士團隊、浙江大學附屬第一醫(yī)院肝膽外科鄭樹森院士團隊、生物芯片北京國家工程研究中心博奧生物集團程京院士團隊、浙江大學附屬第一醫(yī)院感染科李蘭娟院士團隊、解放軍302醫(yī)院傳染病生物治療王福生院士團隊、中國醫(yī)學科學院病原生物學研究所金奇教授團隊、香港大學艾滋病研究中心陳志偉教授團隊、中山大學附屬第一醫(yī)院器官移植何曉順教授團隊、解放軍總醫(yī)院呼吸病重癥診治劉又寧教授團隊、中山大學腫瘤醫(yī)院放射介入治療張福君教授團隊、東南大學附屬中大醫(yī)院重癥醫(yī)學邱海波教授、南京醫(yī)科大學附屬無錫人民醫(yī)院肺移植陳靜瑜教授等13個院士、國家級重點學科團隊，為醫(yī)院的臨床診治和科學研究后續(xù)發(fā)展注入強大的力量。醫(yī)院獲深圳市公立醫(yī)院管理中心2017年度學科建設優(yōu)秀獎。
　　
　　By virtue of the "Project on Famous Universities, Famous Presidents, Famous Teachers" of the Municipal Party Committee and Municipal Government, and with the basic idea of "Flexible Talent Introduction" and the aim of cultivating "self-innovation ability", since 2014, the Hospital has introduced the team of Academician Gao Fu of the Institute of Microbiology of the Chinese Academy of Sciences, the team of Academician Zheng Shusen of the Department of Hepatobiliary Surgery of the First Affiliated Hospital of Zhejiang University, the team of Academician Cheng Jing of the Beijing National Engineering Research Center Bo’ao Bio Group, the team of Academician Li Lanjuan of the Infection Department from the First Affiliated Hospital of Zhejiang University, the team of Academician Wang Fusheng of 302 Hospital of PLA, the team of Professor Jin Qi from the Institute of Pathogenic Biology of the Chinese Academy of Medical Sciences, the team of Professor Chen Zhiwei of the AIDS Research Center of University of Hong Kong, the team of Professor He Xiaoshun of the First Affiliated Hospital of Sun Yat-sen University, the team of Professor Liu Youning of the General Hospital of PLA, the team of Professor Zhang Fujun of the Cancer Hospital of Sun Yat-sen University, Professor Qiu Haibo of Zhongda Hospital affiliated to Southeast University, Professor Chen Jingyu of Wuxi People's Hospital affiliated to Nanjing Medical University, and national key discipline teams, which has injected powerful force into the follow-up development of clinical diagnosis, treatment and scientific research of the hospital. In addition, the hospital won the Excellent Award for Discipline Construction of Shenzhen Public Hospital Management Center in 2017.
　　
　　
　　2017年5月，深圳市第三人民醫(yī)院正式獲得廣東省衛(wèi)計委頒發(fā)的肝臟移植、腎臟移植“牌照”。醫(yī)院現(xiàn)全力建設器官移植中心，并以器官移植工作為龍頭推動醫(yī)療水平綜合發(fā)展，打造醫(yī)院核心競爭力。截止2019年7月，完成身后器官捐獻和肝、腎器官移植手術共152例，在深圳市乃至廣東省引起了強烈的關注和良好反響。
　　
　　In May 2017, the Third People's Hospital of Shenzhen was officially granted the "license" of liver and kidney transplantation issued by the Health Commission of Guangdong Province. The Hospital is now making every effort to build an organ transplantation center, and promote the comprehensive development of medical level with organ transplantation as the leading task, so as to build the core competitiveness of the Hospital. As of March 7, 2019, 114 cases of posthumous organ donation and liver and kidney organ transplantation have been completed in the hospital. All the OTPs have been in good condition, which has aroused strong concern and good response in Shenzhen and even Guangdong Province.
　　
　　
　　 2018年2月26日，深圳市第三人民醫(yī)院、中國科學院病原微生物與免疫學重點實驗室、華大基因、中興網(wǎng)信-巴西FIOCRUZ基金會建立傳染病預防與研究中心。中-巴將建立新發(fā)突發(fā)傳染病信息共享網(wǎng)絡、病原數(shù)據(jù)交互網(wǎng)絡；中國分部落地在深圳市第三人民醫(yī)院，負責流行性疾病如流感、基孔肯雅病、寨卡熱、登革熱、黃熱病、奧羅普切熱以及其他感染性疾?。ɡ缃Y核?。┑难芯浚话臀鹘ǔ梢灾袊灾髦R產(chǎn)權設備為核心的檢測實驗室；巴西臨床醫(yī)院建立我國自主知識產(chǎn)權相關檢測產(chǎn)品，抗感染病藥物的推廣驗證實驗室。
　　
　　 On February 26, 2018, the Third People's Hospital of Shenzhen, the Key Laboratory of Pathogenic Microorganisms and Immunology of the Chinese Academy of Sciences, the Beijing Genomics Institute and the ZTE Netcom-Brazil FIOCRUZ Foundation established the Center for the Prevention and Research of Infectious Diseases. China and Brazil will establish the information sharing network for emerging infectious diseases and the interactive network for pathogen data. The China division, based at the Third People's Hospital of Shenzhen, is responsible for the research of epidemic diseases such as influenza, Chikungunya, Zhaika fever, dengue fever, yellow fever, Oropuche fever and other infectious diseases (such as tuberculosis). Brazil has built a testing laboratory with Chinese independent intellectual property equipment as the core. The Brazilian clinical hospital has set up a laboratory for the promotion and validation of anti-infective drugs and products related to intellectual property rights in China.
　　
　　
　　 2019年2月，深圳市第三人民醫(yī)院、廣東省防癆協(xié)會和廣東省預防醫(yī)學會共同主辦了“粵港澳大灣區(qū)傳染病防控合作發(fā)展研討會”，探討如何提高大灣區(qū)結核病和新發(fā)重大傳染病防治能力及學術水平，建立傳染病防控一體化體系。會上，深圳市第三人民醫(yī)院聯(lián)合了香港大學新發(fā)傳染性疾病國家重點實驗室、澳門大學健康科學學院簽訂協(xié)議，共同成立“粵港澳大灣區(qū)新發(fā)重大傳染病應急防治醫(yī)學研究中心”，聯(lián)合粵港澳大灣區(qū)的28家醫(yī)院、防控機構、高等院校作為中心的核心單位。
　　
　　 In February 2019, the Third People's Hospital of Shenzhen, the Anti-tuberculosis Association of Guangdong Province and the Preventive Medicine Association of Guangdong Province co-sponsored the "Guangdong-Hong Kong-Macao Greater Bay Area Seminar on Cooperation and Development of Prevention and Control of Infectious Diseases" to explore how to improve the ability and academic level of prevention and control of tuberculosis and emerging major infectious diseases in the greater bay area and establish an integrated system of prevention and control of infectious diseases.
　　
　　
　　三、實驗室建設
　　
　　 III. Laboratory Construction
　　
　　 作為深圳科研領頭單位之一，醫(yī)院設有深圳市肝病研究所，配套實驗室面積4682㎡，建設有BSL-3實驗室和SPF級動物室，其中生物安全二級實驗室面積3900㎡，BSL-3實驗室391㎡，動物實驗室391㎡，為全市醫(yī)院所獨有。購置的科研設備總價值超過2億。包括illumina事代高通量測序儀、Sequenom Massarray生物芯片質(zhì)譜系統(tǒng)、Zeiss共聚焦顯微鏡、高效液相色普儀、超速離心機、磁珠細胞分選器、激光顯微切割儀等。建立完善了高通量MassARRAY核酸分析平臺、細胞免疫分析技術平臺、分子生物學技術平臺、實驗動物技術平臺，在滿足自身研究需要的同時技術平臺還對國內(nèi)的科研院所進行開放服務，實現(xiàn)了資源和技術共享。實驗室先后與國外著名學府、研究機構進行合作交流，其中包括美國國立衛(wèi)生研究院（NIH）、美國麻省大學醫(yī)學院（UMASS）、美國Trudeau研究所、美國Tufts大學以及澳大利亞悉尼大學等。
　　
　　
　　 As one of the leading scientific research units in Shenzhen, the Hospital has Shenzhen Institute of Liver Diseases, with a supporting laboratory area of 4682m2 and it has the BSL-3 laboratory and the SPF-level animal laboratory. The second-level laboratory of biosafety covers an area of 3900 m2, the BSL-3 laboratory covers a total of 391 m2 and the animal laboratory covers a total of 391 m2, unique to Shenzhen's hospitals. The total value of scientific research equipment is over RMB 200 million. The equipment includes the Illumina Solexa Genome Analyzer, Sequenom MassArray Biochip Mass Spectrometry System, Zeiss Confocal Microscope, HPLC, UCF, Magnetic Bead Cell Sorter, Laser Microdissector, etc.
　　
　　
　　四、科研成果
　　
　　 IV. Scientific Research Achievements
　　
　　近5年來，醫(yī)院先后承擔國家重大科技專項24項，國家、省自然科學基金33項，累計獲得科研經(jīng)費超過4億元。2012年感染病科引進的香港大學“新發(fā)傳染病研究團隊”獲深圳市“孔雀計劃”資助（2500萬元）。2015年獲得深圳市衛(wèi)生系統(tǒng)首個國家自然科學基金杰出青年基金。先后獲得國家“十二五”傳染病重大科技專項分課題18項，國家“十二五”傳染病重大科技專項牽頭1項。近5年共發(fā)表SCI論文200篇，累計影響因子超過1000分，包括國際頂尖雜志《N Engl J Med.》、《Science》、《Nature》、《Lancet》、《Nat Genent》、《PLoSPathog》等論文10余篇。國家、省、市級獎項9項，獲得發(fā)明專利9項。
　　
　　In the past five years, the Hospital has undertaken 24 major national science and technology projects and 33 national and provincial natural science funds, and has accumulated more than RMB 400 million in scientific research funds. In 2012, the "Emerging Infectious Diseases Research Team" of the University of Hong Kong introduced by the Infectious Diseases Department was funded by the Peacock Program of Shenzhen (RMB 25 million). In 2015, the Hospital was awarded the First National Natural Science Foundation Outstanding Youth Fund of Shenzhen Health System. It has obtained 18 sub-projects on major scientific and technological projects of infectious diseases in the 12th Five-Year Plan and 1 leading project on major scientific and technological projects of infectious diseases in the 12th Five-Year Plan. In the past three years, more than 200 SCI papers have been published, with a cumulative impact factor of over 1000 points. More than 10 papers have been published in top international magazines such as N Engl J Med., Science, Nature, Lancet, Nat Genent, PLoSPathog and so on. The Hospital has also won 9 national, provincial and municipal awards and 9 invention patents.
　　
　　
　　 2018年，醫(yī)院在學科建設方面突飛猛進，在自然出版集團以指數(shù)方式發(fā)布的 “中國醫(yī)院自然指數(shù)”排名全國第87位；在中國醫(yī)學科學院發(fā)布的26個?？瓶萍加绊懥ε琶?，結核病學排名全國第6位，傳染病學排名全國第21位。
　　
　　 In 2018, the Hospital made great progress in discipline construction, ranking 87th in the Natural Index of Chinese Hospitals published by the Natural Publishing Group in the form of index. Among the ranking of 26 science and technology influence specialties released by the Academy of Medical Sciences, the science of tuberculosis ranks 6th in China and the science of infectious diseases rinks 21st in China.
　　
　　五、下一步發(fā)展規(guī)劃
　　
　　 V. Next Development Plan
　　
　　未來五年，醫(yī)院將以打造廣深醫(yī)療高地高水平醫(yī)院為要求，依托結核病國家臨床醫(yī)學研究中心平臺，建成粵、港、澳及珠三角地區(qū)集醫(yī)療、科研、教學與預防保健于一體，國內(nèi)一流、國際先進水平的現(xiàn)代化三級甲等研究型醫(yī)院。一方面將以需求為導向，發(fā)揮區(qū)域協(xié)同作用，系統(tǒng)加強臨床科研資源共建共享，推動生物樣本、醫(yī)療健康大數(shù)據(jù)等資源的高效整合利用，尤其是結核病領域在三年內(nèi)建成國內(nèi)第一、世界一流的結核病綜合學科。另一方面繼續(xù)引進高端人才，加快人才“走出去”步伐，培養(yǎng)臨床研究專業(yè)人才，加強對醫(yī)學科技領軍人才和優(yōu)秀創(chuàng)新團隊的培養(yǎng)，培養(yǎng)一批高素質(zhì)的與世界水平接軌的科研領軍人才和創(chuàng)新團隊。在器官移植事業(yè)上，強有力引進和培養(yǎng)器官移植學科專家團隊，夯實學科內(nèi)涵，全面鋪開建設醫(yī)院器官移植事業(yè)，爭取2019年達到國內(nèi)先進水平，進入大器官移植醫(yī)院第一方陣。同時，醫(yī)院還將積極開展疾病防控領域國際科技交流與合作，將與華大基因、中興通訊、騰訊、邁瑞等一批深圳本地優(yōu)秀企業(yè)和深圳出入境檢驗檢疫局單位合作，推進重大疾病國際科技合作研究網(wǎng)絡的建設，打造國際化臨床科研攻關團隊，以建設結核病國家臨床醫(yī)學研究中心為契機，對標最高最優(yōu)最好，推動深圳醫(yī)療走出國門。
　　
　　In the next five years, in order to build a high-level hospital in Guangzhou-Shenzhen Medical Highland, relying on the platform of National Clinical Research Center for Tuberculosis, the Hospital will be built into a first-class modern research hospital of Class III Grade A in China and internationally, integrating medical treatment, scientific research, teaching and preventive health care in Guangdong, Hong Kong, Macao and the Pearl River Delta. On the one hand, the Hospital will be demand-oriented, play a role of regional synergy, systematically strengthen the joint construction and sharing of clinical research resources, promote the efficient integration and utilization of biological samples, medical and health data and other resources, and especially build the leading domestic and world-class comprehensive discipline of tuberculosis within three years in the field of tuberculosis. On the other hand, the Hospital will continue to introduce high-end talents, speed up the pace of "going out" of talents, train clinical research professionals, strengthen the training of leading medical talents and excellent innovation teams, and cultivate a number of world class high-quality research leading talents and innovation teams. The Hospital will introduce and cultivate the team of experts in the field of organ transplantation, consolidate the connotation of the discipline, and comprehensively develop the cause of organ transplantation, so as to reach the advanced level in China and become one of the large hospitals of organ transplantation in 2019. It will also actively carry out international scientific and technological exchanges and cooperation in the field of disease prevention and control. It will cooperate with a number of excellent local enterprises in Shenzhen such as the Beijing Genomics Institute, ZTE, Tencent and Mindray, and Shenzhen Entry-Exit Inspection and Quarantine Bureau to promote the construction of international scientific and technological cooperation research network for major diseases and build an international clinical research team. Taking the opportunity of building the national clinical research center for tuberculosis, the Hospital will set the highest standard, and promote Shenzhen Medical Service internationally.